Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule

Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference

Anavex Appoints International Alzheimer’s Expert to Scientific Advisory Board

Anavex Reports Fiscal Third Quarter 2015 Financial Results

Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73

Anavex Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

Anavex Presents Positive Initial Phase 2a Study Data with ANAVEX 2-73 showing Early Evidence of Improving Cognition in Patients with Alzheimer’s Disease at AAIC 2015

Anavex to Present Initial Clinical Data from the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer’s Association International Conference (AAIC)

Anavex Strengthens Board of Directors

Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer’s Disease